ReCode Therapeutics
PrivateLast Round
Venture Round
Sep 29, 2025
Est. Valuation
$372M
Total Funding Raised
$386M
Company Overview
ReCode Therapeutics operates in Healthcare & Life Sciences and is based in Menlo Park, California. Its latest recorded funding round was a Venture Round in September 2025.
ReCode Therapeutics is a biotechnology company that specializes in targeted delivery technology utilizing lipid nanoparticles to administer genetic therapies for patients with rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ReCode Therapeutics Comparables
Compare ReCode Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Spirovant Sciences | 86% | |
| NanoVation Therapeutics | 80% | |
| cystetic Medicines | 79% |
For institutional investors. Book with your work email.
ReCode Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Venture Round | Sep 29, 2025 | ||||
| Grant | Nov 18, 2024 | ||||
| Series B Extension | Sep 19, 2023 | ||||
| Grant | Jan 10, 2023 | ||||
| Series B Extension | Jun 29, 2022 | ||||
Series B | Oct 21, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ReCode Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B, Series B Extension |
| MPM Capital | Series A, Series B, Series B Extension |
| Bioluminescence Ventures | Series B, Series B Extension |
| Vida Ventures | Series A, Series B, Series B Extension |
| MPM BioImpact | Series A, Series B |
| Osage University Partners | Series A, Series B, Series B Extension |
| OrbiMed | Series A, Series B, Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 29, 2025
Secured $3M in grant funding.
- Mar 25, 2025
Recognized by San Francisco Business Times and Silicon Valley Business Journal.
For institutional investors. Book with your work email.
ReCode Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ReCode Therapeutics's valuation, stock price, and market status.
Is ReCode Therapeutics a public or private company?
ReCode Therapeutics is a private company.
What is the current stock price of ReCode Therapeutics?
ReCode Therapeutics is a private company, so its shares have no public market price. Caplight tracks ReCode Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ReCode Therapeutics worth (valuation)?
ReCode Therapeutics's valuation is estimated at $372.0M based on funding round data.
Can I buy ReCode Therapeutics stock?
ReCode Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ReCode Therapeutics's last funding round?
ReCode Therapeutics's most recent funding round was Venture Round on September 29, 2025.
Who are the main investors in ReCode Therapeutics?
Key investors in ReCode Therapeutics include Bioluminescence Ventures, Cystic Fibrosis Foundation, Matrix Capital Management, Pfizer Ventures, Sanofi Ventures.
Will ReCode Therapeutics IPO soon?
No public IPO plans have been announced for ReCode Therapeutics.
How can I track ReCode Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in ReCode Therapeutics's shares on secondary markets.